Evidence map›Paper›PMID 38982917›Full record

ArticleMicroRNA (Shariqah, United Arab Emirates)2024

MicroRNA Biomarkers on Day of Injury Among Patients with Post Concussive Symptoms at 28-Days: A Prospective Cohort Study.

Biswadev Mitra, Brendan Major, Jonathan Reyes, Nanda Surendran, Jesse Bain, Lauren P Giesler, William T O'Brien, Edmond Sorich, Catherine Willmott, Sandy R Shultz and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in MicroRNA (Shariqah, United Arab Emirates), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Biswadev MitraEmergency & Trauma Centre, The Alfred Hospital, Melbourne, VIC, Australia.ORCID 0000-0002-0508-2450
Brendan MajorDepartment of Neuroscience, The School of Translational Medicine, Monash University, Melbourne, VIC, Australia.
Jonathan ReyesMonash-Epworth Rehabilitation Research Centre (MERRC), Epworth Hospital, Melbourne, VIC, Australia.
Nanda SurendranEmergency & Trauma Centre, The Alfred Hospital, Melbourne, VIC, Australia.
Jesse BainDepartment of Neuroscience, The School of Translational Medicine, Monash University, Melbourne, VIC, Australia.
Lauren P GieslerDepartment of Neuroscience, The School of Translational Medicine, Monash University, Melbourne, VIC, Australia.
William T O'BrienDepartment of Neuroscience, The School of Translational Medicine, Monash University, Melbourne, VIC, Australia.
Edmond SorichGlia Diagnostics, Neutral Bay, NSW, Australia.
Catherine WillmottMonash-Epworth Rehabilitation Research Centre (MERRC), Epworth Hospital, Melbourne, VIC, Australia.ORCID 0000-0001-8517-9035
Sandy R ShultzDepartment of Neuroscience, The School of Translational Medicine, Monash University, Melbourne, VIC, Australia.ORCID 0000-0002-2525-8775
Terence J O'BrienDepartment of Neuroscience, The School of Translational Medicine, Monash University, Melbourne, VIC, Australia.ORCID 0000-0002-7198-8621
Jeffrey V RosenfeldDepartment of Neurosurgery, The Alfred Hospital, Melbourne, VIC, Australia.ORCID 0000-0003-3827-9898
Stuart J McDonaldDepartment of Neuroscience, The School of Translational Medicine, Monash University, Melbourne, VIC, Australia.ORCID 0000-0001-5190-3179

Funding

Defence Health Foundation
6 · The paper itself

Abstract

backgroundAfter mild traumatic brain injury (mTBI), some patients experience symptoms that persist for weeks to months. Recovery from mTBI is primarily assessed using selfreported symptom questionnaires. Blood biomarkers, including microRNA species, have shown promise to assist diagnosis of mTBI, however, little is known about how blood microRNA measures might predict symptom recovery.

objectiveThe aim of this study was to investigate the variances in plasma microRNAs on the day of injury between individuals with mTBI who report post-concussive symptoms at the 28- day mark and those who do not.

methodsPatients who presented to an adult, tertiary referral hospital emergency department on the day of the injury and were diagnosed with isolated mTBI (n=35) were followed up for 28 days. Venous blood samples were collected and symptom severity was assessed using the Rivermead Post-Concussion Symptom Questionnaire (RPQ) on the day of injury and at 28 days. Patients who reported ongoing symptoms of total RPQ score ≥10 or at least one symptom severity ≥2, were compared to those with lesser symptom severity or symptom resolution.

resultsThere were 9 (25.7%; 95%CI: 12.5-43.3) patients who reported persistent symptoms. Day of injury plasma miR-223-3p levels were significantly higher in individuals with ongoing symptoms compared to those without, however, no such differences were observed for miRs 142- 3p, 423-3p, 32-5p, 144-3p, and let-7f-5p.

conclusionAcute plasma miR-223-3p levels appear to detect patients who later have persistent symptoms after mTBI. The results demonstrate the potential utility for such biomarkers to assist in decisions towards early referral for therapy after mTBI.

Indexed as

BiomarkersMicroRNAsPost-Concussion SyndromeAdultBrain ConcussionFemaleHumansMaleMiddle AgedProspective StudiesSurveys and QuestionnairesYoung AdultBiomarkersMicroRNAsbiomarkersbrain concussionBrain injuriesMicroRNAs.post-concussion syndrometraumatic

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.